Alnylam Pharmaceuticals
ALNY
#600
Rank
C$46.48 B
Marketcap
$360.43
Share price
4.37%
Change (1 day)
43.08%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.90. In 2022 the company made an earnings per share (EPS) of -$13.34 a decrease over its 2021 EPS that were of -$10.34.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-58.79%
2022-$13.3429.03%
2021-$10.34-3.36%
2020-$10.70-8.48%
2019-$11.697.67%
2018-$10.8639.74%
2017-$7.7712.94%
2016-$6.8838.84%
2015-$4.95-32.88%
2014-$7.38259.44%
2013-$2.05-31.25%
2012-$2.9952.94%
2011-$1.9530.77%
2010-$1.49-8.77%
2009-$1.6478.13%
2008-$0.92-70.78%
2007-$3.1499.09%
2006-$1.58-43.88%
2005-$2.81-82.33%
2004-$15.93-59.23%
2003-$39.07

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.44-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$53.65-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$11.24 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.39-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.43-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.37-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.57-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.87-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel